TMDX Company Profile and Key Details

TMDX has shown sold momentum, gaining 5.4% over the past week and 20.66% over the past quarter, though year-to-date performance is up 16.67%. Short-term trend indicators are bearishly aligned (SMA20 -5.8%, SMA50 -3.39%, SMA200 5.73%). The stock’s 14-day RSI is 42.88 (neutral), while the ATR of 7.03 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -16.92% below its high and over 108.79% above its low. Average 10-day trading volume of 783.43 thousand shares is in line with the 3-month average of 763.04 thousand, indicating normal recent market interest.

TransMedics Group, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.09. This means the shares are trading below this model’s fair value.

Wall Street analysts project EPS growth of 52.57% annually over the next five years. The latest quarter delivered EPS of $0.66. The next quarter is forecast at $0.39. Next year's EPS is expected at $44.85. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 8 Buy ratings, 3 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $166.00 to $104.00. The high target offers 28.09% upside. The low target suggests -19.75% downside. The mean target is $140.00. This offers 8.02% upside. TransMedics Group, Inc. earnings surprise history is a mixed track record. The quarter that ended October 29, 2025, missed forecasts by 78.38%. The prior quarter beat by 91.67%. Over the last six quarters, Apple has recorded several small beats. These include 66.67% in July 31, 2024.

TransMedics Group, Inc. (NASDAQ:TMDX) closed at $129.60 USD, losing -$0.77 (-0.59%) from the previous close of $130.37. The stock is currently mid-range between its 52-week high and low $62.07 and $156.00. With a market capitalization of about $4.43 billion, TransMedics Group, Inc. is classified as a mid-cap and shows higher-than-market volatility (beta ~1.98). Key stats such as the average daily volume over the past year has been around 764.47 thousand shares, in line with its 52-week average. Headquartered in Andover, MA, TransMedics Group, Inc. operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Waleed H. Hassanein, the company employs approximately 728 people and listed since May 02, 2019. TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.

TransMedics Group, Inc. has 34.09 million shares outstanding. The public float is 32.96 million shares, elevated short interest at 41.68% of float. This equals 8.27 million shares. The short ratio is 7.15 days. Institutional investors hold 114.66% of the float. Insiders own 2.95%. Hassanein Waleed H holds 495.01 thousand shares, TOBIN JAMES R has 173.15 thousand shares and Khayal Tamer I has 36.04 thousand shares. Over the past six months, insider transactions show net selling. They sold 13.06 thousand shares across 4 transactions.

TransMedics Group, Inc. trades at a P/E ratio of 48.22, slightly above the S&P 500 average, with a price-to-sales ratio of 7.83 and a price-to-book ratio of 12.46 reflecting a rich premium to book value. The P/FCF stands at 36.74, also above market averages. Compared to sector medians, TransMedics Group, Inc. P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Our AI price prediction model suggests that TransMedics Group, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 3.69%, with price expected at $134.38 by February 18, 2026, within a range of $129.01 to $139.90 3-Month Outlook: Projected rise of 61.47%, reaching $209.26 by May 05, 2026, with a range of $201.32 to $219.97. 1-Year Outlook: Projected gain of 19.47%, with price at $154.83 by February 04, 2027, within a range of $145.97 to $164.17.

TransMedics Group, Inc. (NASDAQ:TMDX) shares are up 16.67% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows TransMedics Group, Inc. trading at a premium to the broader market with a P/E of 48.22. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $120.74, suggesting -6.84% downside. Our AI forecast model points to short-term strength (3.69% over two weeks), a medium-term rise (61.47% over three months), and a longer-term gain (19.47% over one year), with expected trading ranges indicating moderate volatility.